- Home
- CV Renal Metabolic
CV Renal Metabolic
Severe Hypertriglyceridaemia: Defining the Disease and Its Management
- 1.00
Published:
Learning objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states
Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention
- 1.00
Published:
Learning objectives
- Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
- Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
- Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
- Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
- Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
- Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
The Rise of CVRM Medicine: Managing Common Co-morbidities as One
- 3.00
Published:
Learning objectives
- Describe the link between T2DM, CKD and ASCVD
- State the importance of early and effective intervention in managing CVRM disease progression
- List the guideline directed therapeutic targets in CVRM disease
- Select appropriate patients for holistic CVRM management
- Recall trial data for novel therapeutic agents that carry benefit for CVRM outcomes
- Develop a holistic management strategy for CVRM disease with an evidence-based impact on clinical outcomes
Renal Denervation In The Real World: Practical Guidance For New Users
- 1.00
Published:
Learning objectives
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials